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Ab s t r Ac t
Background: Experimental tumors have great importance in modeling, and Ehrlich ascites carcinoma (EAC) is one of the most common 
tumors. EAC is referred to as an undifferentiated carcinoma and is originally hyperdiploid, has high transplantable capability, no-regression, 
rapid proliferation, shorter life span, 100% malignancy, and also does not have tumor-specific transplantation antigen. The current concepts 
that radiotherapy alone or with cancer chemotherapy is administered at a dose to the maximum a patient can tolerate before the onset of 
severe and even life-threatening toxicity is still in wide clinical use. This study was conducted to evaluate the response of radiotherapy in the 
treatment of EAC. Materials and Methods: A mouse bearing the tumor strain was taken from our laboratory in the Department of Pathology, 
IPGMER, Kolkata, where the strain was being maintained serially by inoculation of malignant cells into healthy mice every 8–10 days. In our 
work, altogether 25 mice were taken for each set of experimental work. They were divided in four groups of 5–10 mice in each group. The 
various parameters to assess the response of various therapeutic schedules were regression of tumor by decrease in body weight of mice and 
decrease in abdominal girth; cell count of ascetic fluid and morphological changes of tumor cells after treatment with drugs and to study the 
percentage viability of the cells. Results: All the mice in Group I gained weight steadily. Mice of Group II were unaffected by single dose whole 
body radiation and they behaved as mice of Group I. All mice of Group III died within 20–25 days. Conclusion: Cell changes were observed 
but not as marked. Cell viability was as high as 65% after treatment as compared to tumor control which showed a viability of about 75%. 
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In t r o d u c t I o n
Experimental tumors have great importance for the purposes of 
modeling, and Ehrlich ascites carcinoma (EAC) is one of the most 
common.[1] It appeared first as a spontaneous breast cancer in a 
female mouse (Aktaş, 1996[2]; Taşkin, 2002[3]), and then Ehrlich and 
Apolant (1905)[4] used it as an experimental tumor by transplanting 
tumor tissues subcutaneously from mouse to mouse.
In the early 1900s, the famous German chemist Paul Ehrlich 
set about developing drugs to treat infectious diseases. He was 
the one who coined the term “chemotherapy” and defined it as 
the use of chemicals to treat disease. He was also the first person 
to document the effectiveness of animal models to screen a 
series of chemicals for their potential activity against diseases, 
an accomplishment that had major ramifications for cancer drug 
development. In 1908, his use of the rabbit model for syphilis led 
to the development of arsenicals to treat this disease. Ehrlich was 
also interested in drugs to treat cancer, including aniline dyes 
and the first primitive alkylating agents, but apparently was not 
optimistic about the chance for success.[5]
For most primary tumors, the treatment of choice is 
surgery and radiotherapy, which measures can be very 
effective for controlling localized tumors and indeed surgery 
and radiotherapy dominated the field of cancer therapy into 
the 1960s. However, at the time of diagnosis, the majority of 
cancers have already microscopically metastasized throughout 
the body, leading to recurrent disease in the majority of cancer 
patients. Today, the various modes of therapy that is available 
for the treatment of cancers are surgery, chemotherapy, 
radiotherapy, endocrine therapy, and immunotherapy. Extensive 
surgery is probably one of the best modes of therapy if there is 
no metastasis. Chemotherapy and radiotherapy come next to 
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surgery. The usefulness of one over the other depends on the 
type of cancer.[6]
Different tumor strains and different animals including rats, 
mice, and dogs have been used to assess the antitumor activity 
of a drug. Most of the antineoplastic drugs are having extensive 
adverse effects with efficacy and in high doses that limit the 
usefulness of any drugs except hormone.[7]
Tumor radiotherapy is a technique that is used to inhibit and 
control growth, metastasis, and proliferation of malignant tumor 
cells using various types of ionizing radiation. It needs no further 
explanation of the effects of radiation of cells since a great deal of 
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it has been mentioned. This experiment was conducted to see the 
effect of only radiotherapy.
ob j e c t I v e s
This study was conducted to evaluate the response of radiotherapy 
in the treatment of EAC. The various parameters to assess the 
response of various therapeutic schedules were as follows: 
1. To assess the regression of tumor by decrease in body weight 
of mice and decrease in abdominal girth.
2. To study the cell count of ascetic fluid after treatment with 
radiotherapy.
3. To study morphological changes of tumor cells after 
subjecting it to antineoplastic drug.
4. To study the percentage viability of the cells.
5. To study the animal survival.
MAt e r I A l s A n d Me t h o d s
Transplantation of EAC in mice (ascetic form): The proliferation 
of malignant cells of the EAC strain simulates the biology of 
any neoplasia. Hence, this study forms a tumor model on which 
different anti-neoplastic agents have been tried to study the kind 
of therapy which would form the best mode of treatment.
Tumor Strain
A mouse bearing the tumor strain was taken from our laboratory 
in the Department of Pathology, IPGMER, Kolkata, where the strain 
was being maintained serially by inoculation of malignant cells 
into healthy mice every 8–10 days. The mouse that was taken had a 
huge ascites from which cells were taken to inoculate mice further. 
Male Swiss albino mice weighing about 16–18 gm were chosen for 
our study.
Transplantation
At first a preliminary diagnosis was made regarding the presence of 
ascites in the mice by noting the gain in weight; gain in abdominal 
girth and by palpating the abdomen. Then with the help of a 
sterile tuberculin syringe and a needle of 21 gauge, 0.5 ml sterile 
normal saline was taken and peritoneal cavity was punctured. This 
0.5 ml sterile normal saline was then pushed into the peritoneal 
cavity to dilute the cell suspension in the immediate vicinity of 
the needle and to separate any fibrin coagulum if formed so that 
the cell suspension could flow out freely. Sample with whitish 
fluid was taken in the syringe. This was then diluted 1:10 in sterile 
physiological saline. A drop from this suspension was taken and 
changed in the Neubauer’s hemocytometer. A cell count was 
done under the optical microscope. The cell suspension was again 
diluted in sterile normal saline to obtain a desired cell suspension 
of about 107 cells/ml.
Simultaneously 0.02 ml cell suspension was taken, diluted in 
the ratio of 1:10 in 0.15% trypan blue made up in physiological 
saline. A drop of cell suspension was taken and a coverslip 
preparation was made to study the viability of the cells. The viable 
cells did not take up any stain whereas the dead cells were stained 
blue. The percentage of viable cells was noted down.
The slides made out from smears of centrifuged deposit 
were stained by hematoxylin and eosine which showed large 
malignant cells with hyperchromatic nuclei with nucleoli and 
scanty cytoplasm [Figure 1]. After having confirmed the presence 
of malignant cells, the suspension was used to inoculate the mice. 
About 0.1 ml of prepared suspension was then taken and diluted 
in 0.4 ml of sterile normal saline and this mixture (0.5 ml) was 
inoculated into each mouse intraperitoneally. Thus, the desired 
cell concentration of 106 cells per inoculums dose was obtained. 
The mice were maintained on pellets prepared by Hindustan Lever 
Company and water ad libitum. The weight of individual mice with 
their abdominal girth was noted before starting the experiment.
Animal Grouping
In our work, altogether 25 healthy mice weighing about 16–18 gm 
were taken. Of them 15 were used to transplant the tumor in 
them. Confirmation of tumor “cells uptake” was done after 7 days 
by aspirating some peritoneal fluid aseptically and examining a 
stained deposit under optical microscope. Once confirmation was 
done that the therapeutic regime was designed and the animals 
were grouped as follows. They were divided into four groups of 
5–10 mice in each group.
•	 Group I: Five healthy mice which were maintained on feed 
and water only. These served as healthy controls.
•	 Group II: Five mice who were given who were given a single 
dose of whole body radiation of 400 rads.
•	 Group III: Five mice who were inoculated with the tumor cells 
and left as such without any treatment. These served as tumor 
controls.
•	 Group IV: Ten tumors bearing mice on whom single whole 
body radiation was given. 
Methods of Observations
Each mouse was weighed in grams before transplantation of 
tumor strain; before starting treatment and 5 days after the 
end of treatment. Abdominal girth of each mouse was taken in 
centimeters in the same schedule as above. The effect of therapy 
was recorded according to the protocol laid by Sugiura (1961).[8]
•	 [+++] Indicates complete inhibition or diminution of ascites.
•	 [++] Marked inhibition indicating no abdominal distension, 
no gross ascites.
Figure 1: A hematoxylin and eosine stained smear of centrifuged 
deposit of peritoneal fluid. Malignant cells like large cells with 
hyperchromatic nuclei with a very thin rim of basophilic cytoplasm 
(×400) confirming successful uptake of tumor cells before starting 
treatment with radiotherapy
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•	 [+] Moderate inhibition indicating slight distension; the fluid 
volume increased only up to ¼ of the volume increased only 
up to ¼ of the volume of the tumor control.
•	 [±] Slight inhibition indicating moderate abdominal 
distension, the fluid volume increased up to ½ of the volume 
of the tumor control.
•	 [-] No effect, indicating marked abdominal distension, the 
fluid volume increased up to ¾ or more of the volume of the 
tumor control.
Survival time of each mouse was noted in relation to the life of 
healthy and drug control mice. In case of any death of any mouse a 
postmortem was carried out to find out the cause of death. Tissues 
from lung, liver, and kidneys were taken and were fixed in 10% 
formalin solution. Tissues were processed as usual and paraffin 
sections were made and stained with hematoxylin and eosine. 
Each set of experiment was done twice.
Confirmation of Successful Transplantation
After about 5–7 days of inoculation any gain in weight and 
abdominal girth was noted. By careful palpation, it was seen that 
the abdomen showed evidence of fluid collection. A peritoneal tap 
was done carefully in an aseptic manner and the fluid obtained 
from the peritoneum was simultaneously diluted in normal 
saline to give a 1:20 dilution. This fluid was seen under the optical 
microscope in a Neubauer chamber. A cell count was done and 
recorded.
A centrifuged deposit of the cell suspension was taken and 
stained with hematoxylin and eosin [Figures 1-4]. The presence of 
large cells with hyperchromatic nuclei, nucleoli, and a thin rim of 
basophilic cytoplasm confirmed the presence of malignant cells in 
the peritoneal fluid. Immediately, a viable count was done and it 
was seen that about 90–95% cells were viable.
re s u lts
All the mice in Group I gained weight steadily. Mice of Group II 
were unaffected by single dose whole body radiation and they 
behaved as mice of Group I. All mice of Group III died within 20–25 
days. Group IV mice showed that the features are shown in Table 1.
All the healthy mice gained in weight and abdominal girth. 
The drug control mice lost some weight. After the treatment, 
morphological features of aspirated cells in smear stained 
in hematoxylin and eosine showed the following features: 
Degeneration of cells marked by vacuolation of cytoplasm; there 
is diminution in size of the nucleus; and the nuclear cytoplasmic 
ratio had diminished [Figures 3 and 4].
This mode of therapy was least effective as compared to 
others given except the triple therapy consisting of actinomycin 
D, mitomycin C, and radiotherapy. Cell viability was as high as 65% 
after treatment as compared to the tumor control which showed a 
viability of about 75%.
dI s c u s s I o n
Anticancer therapy was based and still relies almost exclusively 
on surgical therapy, although associated therapy has developed 
over the past decades: Surgery and/or chemotherapy and/
or radiotherapy, with the development of cryotherapy, 
immunotherapy and in general, the adoption of techniques and 
methodologies used in human oncology.[7]
Figure 2: Cell morphology after treatment with radiotherapy (×400)
Figure 4: A cell showing karyorrhexis after treatment with 
radiotherapy (×400)
Figure 3: Cell viability count 2 h after incubation at 37°C following 
treatment with radiotherapy (×160)
The therapeutic strategy should take into consideration three 
indispensable elements:[7]
•	 The histological nature of the lesion;
•	 The assessment of the extension of the tumor process;
•	 The evaluation of the general disease state.
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Ehrlich-Lettre ascites carcinoma (EAC) is also known as Ehrlich 
cell. It was originally established as an ascites tumor in mice. The 
tumor was cultured  in vivo, which became known as the Ehrlich 
cell. After 1948, Ehrlich cultures spread around research institutes 
all over the world. The Ehrlich cell became popular because it 
could be expanded by  in vivo  passage. This made it useful for 
biochemical studies involving large amounts of tissues. It could 
also be maintained  in vitro  for more carefully controlled studies. 
Culture techniques in large-scale, mice passage are less attractive, 
due to the contamination of the tumor with multifarious host 
inflammatory cells. EAC is referred to as undifferentiated carcinoma 
and is originally  hyper-diploid. The  permeability  to water 
is highest at the initiation of the  S phase  and progressively 
decreases to its lowest value just after  mitosis. Activation heats 
for water permeability vary during the cell cycle, ranging from 
9–14 kca/mole.[9]
EAC is referred to as an undifferentiated carcinoma, and 
is originally hyperdiploid, has high transplantable capability, 
no-regression, rapid proliferation, shorter life span, 100% 
malignancy, and also does not have tumor-specific transplantation 
antigen (Kaleoğlu and İşli, 1977).[10]
EAC has a resemblance with human tumors which are 
the most sensitive to chemotherapy due to the fact that it 
is undifferentiated and that it has a rapid growth rate. The 
examination of a stained smear by hematoxylin and eosins showed 
vacuolation of cytoplasm. The nucleus had become compact. The 
cytoplasm stained an eosinophilic tinge. If compared with the 
control, it can be said that the treatment group showed features of 
cellular degeneration. As we all know, radiation has several effects 
such as breaking of hydrogen bonds, formation of cross linkage 
between adjacent strands or closely apposed regions of the same 
strand, and impairment of the ability of DNA to act as a template 
for synthesis of new DNA strand.[11]
By 2040, 27.5 million new cases of malignancy are expected 
annually if the current prevalence of cancer and global population 
continue to grow at the same rate.[12] In many types of cancer, 
ascites is a prognostic indication of advanced stage; just of cancer 
patients who are diagnosed with ascites live beyond a further 6 
months.[13] Combination therapy has become the base of cancer 
therapy.[14] Fundamentally, the combined agents work in a 
synergistic or additive manner, and thus, the required therapeutic 
dose of each agent is low.[15] The treatment with multiple agents 
enhances the possibility to target all cancer cells including cancer 
stem cells that are responsible for drug resistance and cancer 
recurrence.[16,17]
During tumor treatment, radiation is considered to be a 
“double-edged sword” because it not only affects the proliferation, 
metastasis, and other biological processes of neoplasms, but may 
also genetically modify normal tissues, causing damage to non-
tumor cells, which is a detrimental effect on the body that we do 
not expect. Conventionally, it has been revealed that irradiation 
can directly affect malignant cells by affecting DNA structure 
stability and repair processes, triggering DNA double-strand 
breaks and inducing therapeutic effects against tumor cells, such 
as apoptosis, necrosis, senescence, and abnormal mitosis.[18-20] 
The latest research has shown that irradiation not only disturbs 
the structure of neoplasm cells such as the cell membrane and 
organelles but also interferes with cell signal transduction and 
regulation, changing neoplasm cells immunogenicity, and their 
microenvironment.[21,22] Mouse studies of radiation effects on 
tumor biology have increased the field knowledge about the 
effect on the tumor microenvironment, including cytokine and 
immune cell response to radiation which affects the overall tumor 
response.[23,24]
co n c lu s I o n
Radiotherapy alone had the least damaging effect on the Ehrlich’s 
ascetic tumor cells. Such therapeutic responses may also be found 
in human neoplasia of various kinds, since the biology of neoplasia 
remains the same everywhere. Research on the impact and the 
specific mechanism of radiation on tumors has become a central 
topic in cancer therapy.
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